Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2020 Jul 22:1–14. doi: 10.1080/07391102.2020.1796802

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2020 Informa UK Limited, trading as Taylor & Francis Group

This article is made available via the PMC Open Access Subset for unrestricted re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the COVID-19 pandemic or until permissions are revoked in writing. Upon expiration of these permissions, PMC is granted a perpetual license to make this article available via PMC and Europe PMC, consistent with existing copyright protections.

PMC Copyright notice

Figure 2. — (a) Pharmacophore modeling of the reported 3CLp inhibitors from their bio-active conformation (i) alignment of reported inhibitors displaying their overlapping pharmacophoric points, (ii) the derived Pharmacophore model-1(Ph-1); (b) The plot indicates the correlation between the binding energies of the reported inhibitors and their pharmocophoric similarity with respect to Ph-1 (R = 0.90); (c) (i) pharmacophore modelling of the reported PLp inhibitors from their bio-active conformation (i) alignment of reported inhibitors displaying their overlapping pharmacophoric points, (ii) the derived pharmacophore model-2 (Ph-2); (d) the plot indicates the correlation between the binding energies of the reported inhibitors and their pharmocophoric similarity with respect to Ph-2 (R = 0.92).